TrialJCO oncology practice2025

Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial).

Adrienne G Waks et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.